April 2017

The adverse events report featuring FDA labeling changes for bendamustine hydrochloride, nilotinib, dinutuximab.

The ever-growing number of cancer survivors means that practitioners across the healthcare spectrum need to step up to an active and dynamic role in their care.

An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

The voice of the patient during clinical trials must be captured, to fully record the impact of treatment toxicity and symptoms.

Nurses may think that if they are careful, their routine drug administration activities will not result in hazardous drug leaking and exposure, but even small leaks are problematic.

Patients with cancer know all too well the worry that accompanies waiting for test results. What can healthcare providers do to help?

Language barriers can mean patients put off preventive screenings, and even treatment, for fear of being misunderstood by their healthcare providers.

Many anticancer therapies increase the risk of oral mucositis, leading to dose reduction or treatment delays. There are interventions that can help, and more are under study.